// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

PSORIATIC ARTHRITIS IS ASSOCIATED WITH A METABOLICALLY ADVERSE BODY COMPOSITION PROFILE PREDICTIVE OF GREATER CHD AND TYPE 2 DIABETES RISK – MRI FINDINGS FROM THE IMAPA AND UK BIOBANK STUDIES

L. D. Ferguson - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

PSORIATIC DISEASE AND BODY COMPOSITION: A SYSTEMATIC REVIEW OF THE LITERATURE

T. Blake - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

REAL WORLD EXPERIENCE OF THE IMPACT OF SECUKINUMAB ON DISEASE ACTIVITY AND FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS

S. Batool - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

REAL WORLD EFFICACY OF SECUKINUMAB: A SINGLE CENTRE EXPERIENCE

G. Kasavkar - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

secukinumab

REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

B. Gilbert - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

REAL WORLD EFFECTIVENESS OF SECUKINUMAB IN PSORIATIC ARTHRITIS: FINDINGS FROM A RECENT CROSS SECTIONAL SURVEY OF RHEUMATOLOGISTS AND PATIENTS IN EUROPE

P. G. Conaghan - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

REAL-WORLD ASSESSMENT OF GP2015 (ETANERCEPT BIOSIMILAR, SDZ-ETN): AN INTERIM ANALYSIS OF DATA FROM THE SELF-INJECTION ASSESSMENT QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE COMPACT STUDY

H. Kellner - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Etanercept biosimilar

REAL-WORLD EXPERIENCE ON SWITCHING ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN INFLAMMATORY ARTHRITIS – A RETROSPECTIVE STUDY

S. A. Yeoh - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Adalimumab

REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS

A. Melville - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Rituximab

REDUCTION OF ANTERIOR UVEITIS FLARES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWING ONE YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL: 48-WEEK INTERIM RESULTS FROM A 96-WEEK OPEN-LABEL STUDY

I. Van der Horst-Bruinsma - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Axial spondyloarthritis

Certolizumab pegol

RED CELL DISTRIBUTION WIDTH AND FATIGUE IN AXIAL SPONDYLOARTHRITIS: A SLEEPER SIGNAL

S. Chatterjee - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

RELIABILITY OF COMPOSITE MEASURES FOR THE ASSESSMENT OF PSORIATIC ARTHRITIS

W. Tillett - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

RESEARCHERS’ PERSPECTIVES ON ADHERENCE INTERVENTION RESEARCH AND OUTCOMES IN RHEUMATOLOGY: AN INTERNATIONAL QUALITATIVE STUDY

S. Salmasi - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT?

W. P. Maksymowych - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

REVISION AND VALIDATION OF THE GERMAN VERSION OF THE SYSTEMIC SCLEROSIS QUALITY OF LIFE QUESTIONNAIRE (SSCQOL) WITH MOKKEN SCALE ANALYSIS

A. Kocher - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

RESPONSE TO SMALL MOLECULES IS MOSTLY DRIVEN BY PATIENT GLOBAL ASSESSMENT OF DISEASE: A REAL WORLD OBSERVATION

C. Joseph - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

REVISITING THE REMISSION CRITERIA FOR RHEUMATOID ARTHRITIS BY EXCLUDING PATIENT GLOBAL ASSESSMENT: AN INDIVIDUAL PATIENT META-ANALYSIS INCLUDING 5792 PATIENTS

R. J. O. Ferreira - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

RHEUMATOLOGY ‘HOT CLINIC’ IN A TEACHING HOSPITAL - WHAT CAN BE EXPECTED?

M. Chakravorty - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RHEUMATOLOGY CARE OF MIGRANTS FROM SUB-SAHARAN AFRICA; A QUALITATIVE PILOT STUDY OF PATIENTS’ PERSPECTIVES

Z. Rutter-Locher - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RHEUMATOLOGY PATIENT PERCEPTION OF CARDIOVASCULAR RISKS: A SURVEY AT A TEACHING HOSPITAL

N. Jain - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved